ALK,ROS1的新药rxdx-101,3月31日开临床了
More data about upcoming Ignyta RDX-101 Phase I trial for ROS1 and ALK:"RXDX-101: RXDX-101 is a new chemical entity that we in-licensed from Nerviano Medical Sciences (Nerviano) in October 2013. RXDX-101 is an orally available, selective tyrosine kinase inhibitor of the TrkA, TrkB, TrkC, ROS1 and ALK proteins. RXDX-101 is designed as a targeted therapeutic candidate to treat patients with cancers that harbor activating alterations to TrkA, TrkB, TrkC, ROS1 and ALK. Candidate alterations include gene rearrangements or mutations, splice variants, increased gene copy number and increased gene expression. RXDX-101 is currently in an ongoing Phase I/II study."
from
The phase 1/2a study is now listed on clinicaltrials.gov, but is not yet recruiting and lists no locations.
Inclusion criteria:
--Locally advanced or metastatic solid tumors that have a TrkA, TrkB, TrkC, ROS1, or ALK molecular alteration (non-small cell lung cancer, colorectal cancer, prostate cancer, papillary thyroid cancer, pancreatic cancer, and neuroblastoma)
--Prior cancer therapy is allowed, including crizotinib and investigational drugs (7-day washout if prior therapy had no toxicity)
--Patients with controlled asymptomatic central nervous system involvement are allowed if not taking anticonvulsants
Craig has heard Massachusetts General in Boston will have this trial, and I have heard University of Colorado will probably have it also.
看了要求，排除了脑转，估计不入脑，是不是3代药未知啊 不知道中国什么时候有实验组？ 有新药就值得庆幸，多一条路和办法！ 听说最近中国在研究，望能快些，造福患者。
页:
[1]